VivoSim Labs, Inc.
VIVSEarnings History
Next report: Feb 9, 2027| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.25 | — | $18.0K | — |
| Jul 14, 2026 | $-2.21 | $-2.04 | $40.0K | $54.0K |
| Feb 11, 2026 | $-1.03 | $-2.40 | $26.0K | $50.0K |
| Nov 6, 2025 | $-0.98 | $-2.28 | $28.0K | $50.0K |
| Aug 12, 2025 | $-1.14 | — | $37.0K | — |
| May 30, 2025 | $-3.48 | $-2.28 | $51.0K | — |
| Feb 19, 2025 | $-0.19 | $-2.52 | $24.0K | $44.0K |
| Nov 8, 2024 | $-1.68 | $-3.12 | $30.0K | $41.0K |
News
Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim's NAMkind™ 3D human liver and intestine models show which ones are safe to advance, in weeks rather than years Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim's NAMkind™ 3D human liver and intestine models show which ones are safe to advance, in weeks rather than years
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
iSpecimen (NASDAQ: ISPC - Get Free Report) and VivoSim Labs (NASDAQ: VIVS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Analyst Ratings This is a summary of recent
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans